Mitsubishi Tanabe Pharma enters into a licensing agreement with Viela Bio for inebilizumab, a treatment agent for neuromyelitis optica spectrum disorder, in Japan and other Asian regions

1/2 October 9, 2019 M itsubishi Tanabe Pharma enters into a licensing agreement with Viela Bio for inebilizumab, a treatment agent for neuromyelitis optica spectrum disorder, in J apan and other Asian regions M itsubishi Tanabe Pharma Corporation (M T PC) (H ead O ffice: Chuo-ku, O saka; President & Representative D irector, CEO : M asayuki M itsuka), announced today a licensing agreement with Viela Bio, Inc. (H ead O ffice: M aryland, U .S .), regarding the in-licensing of inebilizumab (generic name), a treatment agent for neuromyelitis optica spectrum disorder (NM O S D ) that is currently under development by Viela Bio. U nder this agreement, M T PC will pay to Viela Bio an upfront licensing fee of $30 million, as well as additional payments contingent on development and commercial milestones. M T PC will also pay royalties on product sales after the product is launched. Inebilizumab is a humanized anti-CD 19 monoclonal antibody that binds with high affinity to CD 19, a protein expressed on a broad range of B cells, including antibody- secreting plasmablasts and some plasma cells. T hese cells are then rapidly depleted from circulation. Inebilizumab is an investigational new drug for which there is no marketing authorization. NM O S D is a rare, life-threatening autoimmune disease of the central nervous system in which the bodyfs immune system attacks healthy cells, most commonly in the optic nerves and spinal cord, resulting in severe damage. NM O S D may cause severe muscle weakness and paralysis, loss of vision, respiratory failure, problems with bowel and bladder function and neuropathic pain.1 T here is currently no cure or approved treatment for NM O S D . T hrough this agreement, M T PC will acquire exclusive development and sales rights for this drug in J apan, S outh K orea, Taiwan, S ingapore, Indonesia, T hailand, M alaysia, the Philippines, and Vietnam. 2/2 M T PC has identified central nervous system diseases as one of its priority disease areas, and moving forward the Company will aggressively work to develop new drugs that address unmet medical needs. [1] National Institute of Neurological Disorders and Stroke, National Institutes of Health https://www.ninds.nih.gov/Disorders/All-Disorders/Neuromyelitis-Optica-Information-Page M itsubishi Tanabe Pharma Corporation Corporate Communications D epartment M edia contacts: T EL:+ 81 6 6205 5119 Investor contacts: T EL:+ 81 6 6205 5110 About M itsubishi Tanabe Pharma M itsubishi Tanabe Pharma, which was founded in 1678, has its headquarters in D oshomachi, O saka, which is the birthplace of J apanfs pharmaceutical industry. W ith business centered on ethical pharmaceuticals, M itsubishi Tanabe Pharma is a well-established company and has the longest history of any listed pharmaceutical company in J apan.* In accordance with the corporate philosophy of gcontributing to the healthier lives of people around the world through the creation of pharmaceuticals,h the Company formulated the key concept of O pen U p the Future under the M edium-Term M anagement Plan 16-20. T hrough the discovery of drugs that address unmet medical needs, centered on its priority disease areas — immuno-inflammation, diabetes and kidney, central nervous system, and vaccines — M itsubishi Tanabe Pharma will strive to contribute to the health of patients around the world. For more information, go to https://www.mt-pharma.co.jp/e/ * Research by T O K YO S H O K O RES EARCH , LT D . About Viela Bio Viela Bio, headquartered in G aithersburg, M aryland, is a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases. For more information, please visit www.vielabio.com

The release as fetched from its publisher. tanabe-pharma.com ↗